Etiologies and clinical features of liver cirrhosis in Lanzhou,China

Shen ZiXiong; Li Min; Zhang JiMing; Li JinZhou; Gou HaiYan; Wang YiXuan

doi:10.3969/j.issn.1001-5256.2020.04.015

Volume 36 Issue 4

Apr. 2020

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2020 > 36(4): 783-787

PDF( 1923 KB)

Etiologies and clinical features of liver cirrhosis in Lanzhou,China

DOI: 10.3969/j.issn.1001-5256.2020.04.015

The First Clinical Medical College of Lanzhou University

Research funding:

Received Date: 2019-12-06
Published Date: 2020-04-20

Abstract

Abstract

Objective To investigate the etiologies and clinical features of patients with liver cirrhosis in Lanzhou,China and the risk factors for liver cirrhosis with primary liver cancer. Methods A retrospective analysis was performed for the medical records of 3496 patients with liver cirrhosis who were diagnosed and treated in Department of Infectious Diseases,The First Hospital of Lanzhou University,from April 2015 to April 2018,including sex,age,family history,past history,personal history,etiology,clinical manifestation,complication,and laboratory examination. The chi-square test was used for comparison of categorical data between groups,and the multivariate logistic regression analysis was used to investigate the risk factors for liver cirrhosis with liver cancer. Results Among the 3496 patients with liver cirrhosis,2209( 63. 19%) had hepatitis B,among whom 2032 patients had complete HBe Ag data,with 807( 39. 71%) HBe Ag-positive patients and 1225( 60. 29%) HBe Ag-negative patients; among these 2209 patients,2207 had HBV DNA data,among whom 1567( 71. 00%) had positive HBV DNA. There were 309 patients( 8. 84%) with hepatitis C,144 patients( 4. 12%) with autoimmune hepatitis,133 patients( 3. 80%)with primary biliary cholangitis,93 patients( 2. 66%) with alcoholic cirrhosis,and 447 patients( 12. 79%) with cryptogenic cirrhosis. Major clinical manifestations included splenomegaly and/or hemocytopenia in 2299 patients( 65. 76%),ascites in 1760 patients( 50. 34%),esophageal varices in 1647 patients( 47. 11%),gastric varices in 1386 patients( 39. 66%),and jaundice in 754 patients( 21. 57%). The main complications included primary liver cancer in 937 patients( 26. 80%),gastrointestinal bleeding in 822 cases( 23. 51%),infection in 697 patients( 19. 94%) [mainly pulmonary infection in 487 patients( 13. 93%) ],and hepatic encephalopathy in 261 patients( 7. 47%). The patients with hepatitis B cirrhosis had a significantly higher incidence rate of primary liver cancer than those with alcoholic hepatitis cirrhosis( χ2= 26. 854,P < 0. 001); the patients with alcoholic cirrhosis had a significantly higher incidence rate of gastrointestinal bleeding than those with hepatitis B cirrhosis( χ2= 5. 031,P = 0. 025); the patients with hepatitis B cirrhosis had a significantly lower incidence rate of hepatic encephalopathy than those with alcoholic cirrhosis( χ2= 40. 903,P < 0. 001). Among the patients with a confirmed diagnosis of primary liver cancer,73. 22% had positive alpha-fetoprotein( AFP) and 26. 78% had negative AFP. Age( odds ratio [OR]= 1. 025,95% confidence interval[CI]: 1. 017-1. 034,P <0. 05),male sex( OR =2. 701,95% CI: 2. 168-3. 365,P <0. 05),positive HBV DNA( OR =1. 361,95% CI:1. 123-1. 649,P < 0. 05),hypertension( OR = 2. 372,95% CI: 1. 845-3. 050,P < 0. 05),and a family history of liver cancer( OR =2. 261,95% CI: 1. 255-4. 075,P < 0. 05) were risk factors for primary liver cancer in patients with liver cirrhosis. Conclusion Hepatitis B is the main etiology of liver cirrhosis in Lanzhou,followed by hepatitis C and autoimmune liver disease. The main clinical manifestations are splenomegaly and/or hemocytopenia,and the main complication is primary liver cancer. Active antiviral therapy and prevention of hypertension may help to reduce the risk of primary liver cancer in patients with liver cirrhosis.
- liver cirrhosis,
- liver neoplasms,
- disease attributes,
- risk factors

FullText(HTML)

References(27)

References

[1] MICHITAKA K,NISHIGUCHI S,AOYAGI Y,et al. Etiology of liver cirrhosis in Japan:A nationwide survey[J]. J Gastroenterol,2010,45(1):86-94.

[2] Chinese Society of Hepatology,Chinese Society of Infectious Diseases. The guideline of prevention and treatment for chronic hepatitis B(2015 version)[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．慢性乙型肝炎防治指南(2015年更新版)[J]．临床肝胆病杂志，2015,31(12):1941-1960.

[3] Chinese Society of Hepatology,Chinese Society of Infectious Diseases. The guideline of prevention and treatment for hepatitis C:A 2015 update[J]. J Clin Hepatol,2015,31(12):1961-1979.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．丙型肝炎防治指南(2015年更新版)[J]．临床肝胆病杂志，2015,31(12):1961-1979.

[4] The Chinese national workshop on fatty liver and alcoholic liverdisease for the Chinese Liver Disease Association. Guidelines for management of alcoholic liver disease:An up dated and revised edition[J]. J Clin Hepatol,2010,26(3):229-232.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组．酒精性肝病诊疗指南(2010年修订版)[J]．临床肝胆病杂志，2010,26(3):229-232.

[5] The Chinese National Workshop on Fatty Liver and Alcoholic Liver disease for the Chinese Liver Disease Association. Guidelines for management of nonalcoholic fatty liver disease:An updated and revised edition[J]. J Chin Hepatol,2010,18(3):163-166.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组．非酒精性脂肪性肝病诊疗指南(2010年修订版)[J]．临床肝脏病杂志，2010,26(2):120-124.

[6] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and management of autoimmune hepatitis(2015)[J]. J Clin Hepatol,2016,32(1):9-22.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．自身免疫性肝炎诊断和治疗共识(2015)[J]．临床肝胆病杂志，2016,32(1):9-22.

[7] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and management of primary biliary cirrhosis(cholangitis)(2015)[J]. J Clin Hepatol,2015,31(12):1980-1988.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J]．临床肝胆病杂志，2015,31(12):1980-1988.

[8] GE JB,XU YJ,WANG C,et al. Internal medicine[M]. version 9,Beijing:People’s Medical Publishing House,2018.(in Chinese)葛均波，徐永健，王辰，等．内科学[M]. 9版，北京:人民卫生出版社，2018.

[9] WANG J,ZHENG GZ. Factors related to esophageal variceal bleeding in patients with liver cirrhosis[J]. Chin J Liver Dis(Electr Version),2019,11(1):42-46.(in Chinese)王娟，郑鸽之．肝硬化食管静脉曲张破裂出血相关因素分析[J]．中国肝脏病杂志(电子版)，2019,11(1):42-46.

[10] AI M,CHEN WC,SHEN W. Survey of 2002 cases of liver cirrhosis:Identification of etiological factors and related complications[J]. J Clin Hepatol,2013,29(5):352-355,362.(in Chinese)艾敏，陈伟婵，沈薇．2002例肝硬化患者的病因及并发症分析[J]．临床肝胆病杂志，2013,29(5):352-355,362.

[11] ZENG G,WU B,LI CD,et al. Analysis of serum HBV DNA load,liver function and HBV-M in 308 patients with chronic hepatitis B[J]. Int J Lab Med,2013,34(14):1908-1910.(in Chinese)曾钢，吴斌，李彩东，等．308例慢性乙肝患者血清HBV DNA载量与肝功能及HBV-M检测结果分析[J]．国际检验医学杂志，2013,34(14):1908-1910.

[12] ZHANG WL,LUO HS. Etiology and related analysis of cirrhosis in Hubei province[J]. Chin J Gastroenterol Hepatol,2019,28(3):325-329.(in Chinese)张维兰，罗和生．湖北地区肝硬化病因及相关分析[J]．胃肠病学和肝病学杂志，2019,28(3):325-329.

[13] LI YM. Epidemiological characteristics of alcoholic liver disease[J]. J Practical Hepatol,2012,15(3):180-182.(in Chinese)厉有名．酒精性肝病的流行病学特点[J]．实用肝脏病杂志，2012,15(3):180-182.

[14] WANG XZ,LIU XF. Etiology and complications of liver cirrhosis:An clinical analysis of 2041 cases[J]. Zhejiang Med J,2017,39(1):37-39.(in Chinese)王秀珍，刘雪峰．2041例肝硬化病因及并发症分析[J]．浙江医学，2017,39(1):37-39.

[15] ZHANG M,SHEN W. Etiological analysis of liver cirrhosis of824 cases[J]. Chongqing Med,2006,35(5):438-439,441.(in Chinese)张鸣，沈薇．824例肝硬化病因及相关分析[J]．重庆医学，2006,35(5):438-439,441.

[16] ZHENG YC,HAN C,LI YW,et al. Comparative study on etiology and complications of liver cirrhosis in a 5-year period[J]. Chin J Practical Internal Med,2019,39(3):278-281.(in Chinese)郑银城，韩超，李艳伟，等．2012年与2017年3065例肝硬化病因及其并发症对比分析[J]．中国实用内科杂志，2019,39(3):278-281.

[17] BULUHAN HL,FENG J,FANG XT,et al. Clinical features and possible etiology of cryptogenic cirrhosis in Xinjiang[J]. World Chin J Digestol,2014,22(8):1135-1140.(in Chinese)布鲁汗·哈兰，冯娟，范晓棠，等．新疆地区隐源性肝硬化的临床特征及可能病因[J]．世界华人消化杂志，2014,22(8):1135-1140.

[18] SCHOUTEN JN,GARCIA-PAGAN JC,Valla DC,et al. Idiopathic non cirrhotic portal hypertension[J]. Hepatol,2011,54(3):1071-1081.

[19] XU J. Etiological analysis and clinical characteristics of liver cirrhosis in elderly patients[J]. West China Med J,2016,31(7):1209-1212.(in Chinese)徐进．老年肝硬化病因及临床特点分析[J]．华西医学，2016,31(7):1209-1212.

[20] MING L,THORGEIRSSON SS,GAIL MH,et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong,China[J]. Hepatology,2002,36(5):1214-1220.

[21] SAIGO K,YOSHIDA K,IKEDA R,et al. Integration of hepatitis B virus DNA into the myeloid/lymphoid or mixed-lineage leukemia(MLL4)gene and rearrangements of MLL4 in human hepatocellular carcinoma[J]. Hum Mutat,2008,29(5):703-708.

[22] MERCEDES F,DAVID S,JORDI B,et al. Angiogenesis in liver disease[J]. JHepatol,2009,50(3):604-620.

[23] CASADEI GARDINI A,SCARPI E,MARISI G,et al. Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib:Results from a retrospective analysis of the HCC-AVR group[J]. Oncotarget,2016,7(12):15243-15251.

[24] LAINE L. Upper gastrointestinal bleeding[J]. Clin Upd Am Soci Gastro End,2007,14(9):1-4.

[25] FAN ZL,XIN KF. Value of coagulation markers and platelet parameters in predicting gastrointestinal bleeding in patients with cirrhotic portal hypertension[J]. Clin J Med Offic,2019,47(9):936-937.(in Chinese)范子玲，辛克锋．凝血指标与血小板参数在肝硬化门静脉高压患者消化道出血中预测价值研究[J]．临床军医杂志，2019,47(9):936-937.

[26] GONZALEZ-GONZALEZ JA,GARCIA-COMPEAN D,VAZQUEZELIZONDO G,et al. Nonvariceal upper gastrointestinal bleeding in patients with liver cirrhosis. Clinical features,outcomes and predictors of in-hospital mortality. A prospective study[J]. Ann Hepatol,2011,10(3):287-295.

[27] LIU M,YAN C,LUO FL. Analysis of risk factors for hepatic encephalopathy in patients with severe hepatitis[J]. Practical J Clin Med,2019,16(4):108-110.(in Chinese)刘梦，严超，罗凤莲．重症肝炎患者并发肝性脑病的危险因素分析[J]．实用医院临床杂志，2019,16(4):108-110.

Relative Articles

[1]	Jing KUANG, Shuangqin TENG, Tongtong SHEN, Yiran YAN, Wei WANG, Chuan SHEN, Caiyan ZHAO. Risk factors for portopulmonary hypertension in liver cirrhosis and construction of a predictive model[J]. Journal of Clinical Hepatology, 2024, 40(9): 1802-1806. doi: 10.12449/JCH240914
[2]	Yichen ZHU, Chunxia SHA, Chunsun FAN, Tiejun ZHANG. Risk factors for liver cancer in chronic hepatitis B patients and construction of a nomogram prediction model[J]. Journal of Clinical Hepatology, 2024, 40(12): 2441-2449. doi: 10.12449/JCH241214
[3]	Xiaoyan MA, Yun CHEN, Jiacheng LIU, Jie LI, Chao WU. Clinical features and related risk factors of chronic hepatitis B patients with concomitant minimal hepatic steatosis[J]. Journal of Clinical Hepatology, 2023, 39(1): 63-69. doi: 10.3969/j.issn.1001-5256.2023.01.010
[4]	Siqin LIU, Xiaomei WANG, Xia LI, Luwen LIANG, Ke WANG, Rui WANG. Covert hepatic encephalopathy in liver cirrhosis: Risk factors and prognosis[J]. Journal of Clinical Hepatology, 2022, 38(2): 359-364. doi: 10.3969/j.issn.1001-5256.2022.02.020
[5]	Yu LIU, Xue MEI, Yuyi ZHANG, Ying ZOU, Zhengguo ZHANG, Hongying GUO, Wei YUAN, Jiefei WANG, Zhiping QIAN. Clinical features and risk factors of acute hepatitis E with severe jaundice[J]. Journal of Clinical Hepatology, 2021, 37(3): 565-569. doi: 10.3969/j.issn.1001-5256.2021.03.013
[6]	Deliang HUANG, Wei DAI, Jun CHEN, Xiaoguang YE. Clinical features of liver injury induced by anti-tuberculosis drugs and related risk factors[J]. Journal of Clinical Hepatology, 2021, 37(10): 2369-2375. doi: 10.3969/j.issn.1001-5256.2021.10.022
[7]	Tian Tian, Hu WenWei, Li Xue, Li Ji, Zhang Dan, Li ZhangZheng. Metabolic characteristics of nonalcoholic fatty liver disease and related risk factors in non-obese population[J]. Journal of Clinical Hepatology, 2020, 36(6): 1310-1313. doi: 10.3969/j.issn.1001-5256.2020.06.024
[8]	LI ZhengHong, DONG YuWei, LU LunGen. Risk factors,diagnosis,and updated classification of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2411-2414. doi: 10.3969/j.issn.1001-5256.2020.11.003
[9]	Ruan FangMing, Li BiMin. Risk factors for the formation of portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 182-185. doi: 10.3969/j.issn.1001-5256.2020.01.043
[10]	Lyu Jing, Dong SiSi, Gu HongTu, Zhao ZhangQing, Liu ChengHai. TCM syndrome characteristics of portal vein thrombosis in patients with liver cirrhosis and related risk factors[J]. Journal of Clinical Hepatology, 2019, 35(10): 2210-2213. doi: 10.3969/j.issn.1001-5256.2019.10.016
[11]	Zhang Dan, Feng GuoHe. Current research status of nosocomial infection in patients with severe liver diseases[J]. Journal of Clinical Hepatology, 2019, 35(1): 213-216. doi: 10.3969/j.issn.1001-5256.2019.01.047
[12]	Liu HongJin, Bao ChunMei, Bai WenLin, Li YinYin, Rong GuangHua, Lu YinYing, Chen Yan, Liu Ze, Cheng JiaMin, Ceng Zhen. Risk factors for infectious complications in primary liver cancer[J]. Journal of Clinical Hepatology, 2018, 34(5): 1033-1037. doi: 10.3969/j.issn.1001-5256.2018.05.021
[13]	Chang XiuJuan, Lu YinYing, Rong GuangHua, Liu Ze, Chen Yan, Xu GuiLin, Gao XuDong, Lou Min, Wang ChunPing, Yang YongPing, Ceng Zhen. Risk factors for vascular invasion of primary liver cancer[J]. Journal of Clinical Hepatology, 2018, 34(5): 1038-1041. doi: 10.3969/j.issn.1001-5256.2018.05.022
[14]	Guo XiaoDi, Sun ShaSha, Li WenDong, Shen YanJun, Sun Wei, Ding XiaoYan, Chen JingLong. Clinical features of patients with Barcelona Clinic Liver Cancer stage C primary liver cancer and related prognostic factors: An analysis of 140 cases[J]. Journal of Clinical Hepatology, 2018, 34(7): 1456-1461. doi: 10.3969/j.issn.1001-5256.2018.07.019
[15]	Ding YuPing, Li Hai, Zhang Wen, Xia ShiHai, Bi Xun. Epidemiological characteristics of nonalcoholic fatty liver disease with elevated alanine aminotransferase and related risk factors[J]. Journal of Clinical Hepatology, 2017, 33(12): 2355-2360. doi: 10.3969/j.issn.1001-5256.2017.12.020
[16]	Zhou RenHua, Li Peng, Zhang YanTing, Yang Hua, Yang ShaoQi. Clinical manifestations of portal vein thrombosis and related risk factors in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(2): 275-278. doi: 10.3969/j.issn.1001-5256.2016.02.015
[17]	Ai YeQing, Zhang ChengHua, Liu HuiFang. Risk factors for postoperative pulmonary infection in patients with primary liver cancer[J]. Journal of Clinical Hepatology, 2016, 32(7): 1334-1337. doi: 10.3969/j.issn.1001-5256.2016.07.024
[18]	Hu CaiXia, Zheng JiaSheng, Lin Wei, Cui ShiChang. Analysis of risk factors for early recurrence after microwave ablation for primary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(2): 228-231. doi: 10.3969/j.issn.1001-5256.2015.020
[19]	Yin TianSheng, Yi YaYang, Mao XiXian, Li DeWei. Meta-analysis of risk factors for posthepatectomy liver failure in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(10): 1009-1014. doi: 10.3969/j.issn.1001-5256.2014.10.009
[20]	Wang Hong. Risk factors for patients with cirrhosis developed renal dysfunction[J]. Journal of Clinical Hepatology, 2004, 20(2): 101-102.

Supplements(0)

Cited By

Cited by

Periodical cited type(11)

1.	郑双，王岩，荀蕾，李琼，祁小龙，谷野，李立竹，陶竹，关斌，王拱辰，张怀斌，郑俐婷，徐峰，胡浩，刘星，吕呈，李欣悦，张朕，张彤彤. 辽宁地区肝硬化病因变迁及食管胃底静脉曲张出血防治现状调研. 中国医学创新. 2023(29): 77-81 .
2.	吴泽生，姚秋艳，杨波. 大理地区肝硬化病因及并发症变化分析. 肝脏. 2023(10): 1167-1170 .
3.	佟印妮，郑吉敏，韩丹，江萍，王存凯，王玉珍，白云. 986例肝硬化患者病因及临床特点分析. 肝脏. 2022(08): 871-873+880 .
4.	卓玛，伊比然恨，丹珍朗赛，索朗卓玛，次央(大)，邓增曲珍. 拉萨地区571例肝硬化患者的病因构成及其临床特征分析. 西藏科技. 2022(10): 19-23 .
5.	杨文康，张俊，王淑秋，祥巴央宗，杨翠萍. 我国云南香格里拉地区104例肝硬化患者的病因及临床特征分析. 诊断学理论与实践. 2022(06): 730-734 .
6.	纪东玲，次仁央金，王中华，李康. 西藏地区758例肝硬化患者临床分析. 现代医学与健康研究电子杂志. 2021(01): 112-114 .
7.	黄坚灵. 肝炎后肝硬化患者医院肺部感染的临床特征及危险因素分析. 名医. 2021(01): 118-120 .
8.	周荃，杨丽晖，蒋芳清. 直接抗病毒药物改善HCV相关肝细胞癌患者远期预后效果的Meta分析. 临床肝胆病杂志. 2021(08): 1836-1840 . 本站查看
9.	陈香妮，李淑芳，袁超. 桃红化浊汤联合恩替卡韦治疗慢性乙型肝炎肝硬化（湿热蕴结证）临床疗效及安全性. 中国肝脏病杂志(电子版). 2021(03): 9-15 .
10.	王能亮，汪洋. 肝硬化合并消化道出血15例的病例分析报告. 智慧健康. 2021(25): 15-17 .
11.	闫圆，李小全. 基于Logistic回归分析构建联合检测因子模型诊断原发性肝癌的价值分析. 内科. 2021(05): 602-607 .

Other cited types(8)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1611) PDF downloads(233)

Etiologies and clinical features of liver cirrhosis in Lanzhou,China

DOI: 10.3969/j.issn.1001-5256.2020.04.015